Sensyne Health plc announced that it has signed a Strategic Research Agreement (SRA) with Sentara Healthcare ("Sentara"), a leading healthcare system serving patients in Virginia and northeastern North Carolina through 12 acute hospitals with more than 300 sites of care. The new agreement is Sensyne's third U.S. partnership since launching in the U.S. in December 2020. The addition of Sentara's 3.6 million patients brings Sensyne's combined total of de-identified patient data for medical research to 21.7 million patients. The partnership combines both life sciences research and healthcare algorithm development that will deliver value back to Sentara and its patients. The agreement will enable the ethical application of clinical AI research by Sensyne through analysing Sentara's patient dataset to improve patient care and accelerate medical research. As part of a collaboration agreement, Sentara also becomes the first of several U.S. health systems that will partner with Sensyne to implement new clinical algorithms to support patients with CKD and CHF.